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Schematic depicting that different metastases obtained from the same patient harbors 
limited heterogeneity, which could inform treatment options. 
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It has been more than a year since the Obama administration launched the Precision Medicine 
Initiative. For precision medicine to be effective for cancer treatment, molecular aberrations in 
cancers of the same histological classification should be distinct between patients. However, another 
critical feature that remains largely untested is that different tumors from the same patient should 
harbor limited molecular heterogeneity. A new Fred Hutch study from Dr. Pete Nelson’s Laboratory 
(Public Health Sciences, Clinical Research and Human Biology Divisions) led by Ilsa Coleman in the 
Nelson Lab and Akash Kumar, a graduate student in Dr. Jay Shendure’s Lab (Genome Sciences, 
UW) and published in Nature Medicine, suggests that at least for prostate cancer, this is indeed the 
case. 
An estimated 27,000 men die of metastatic prostate cancer (mPC) each year in the United States, 
and the standard of care for this disease, largely unchanged for half a century, is androgen 
deprivation therapy (ADT). While ADT represented a pioneering precision medicine approach when 
first introduced it has limitations, namely, most patients undergoing ADT eventually succumb to 
metastatic castration-resistant prostate cancer (mCRPC). A previous study with the Nelson Lab 
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cataloged the suite of recurrent molecular aberrations in mCRPC, whereas the current study sought 
to determine whether a single metastatic tumor from any given patient provides a reliable 
assessment of the driver mutations for all metastases in that same patient. The study began by 
determining the spectrum of mutations (by whole exome sequencing), copy number alterations (by 
array comparative genomic hybridization) and RNA levels (microarray) from 176 primary or 
metastatic tumors obtained from 63 men. Recurrent alterations in genes such as AR (encoding the 
androgen receptor), ERG, TP53 and RB1, all previously known to occur in mCRPC, were found. 
Despite all men having undergone ADT, robust AR activity was detected in the majority of men 
(88%) and AR activity scores, AR expression and AR genomic aberrations were highly similar 
between metastases derived from any single patient. Next, the researchers tested whether this 
concordance could be applied to other features of the tumor by incorporating copy number 
alterations, mutations and gene expression in their integrated analysis. Together with unsupervised 
clustering, these analyses revealed that all tumors taken from the same individual cluster together, 
whereas tumors from other men were always distinct. The investigators also evaluated a 31-gene 
signature of cell cycle progression (CCP), shown to be associated with prostate cancer mortality. 
Surprisingly, AR activity was inversely correlated with CCP, a result that was corroborated by 
examining the growth of cultured prostate cancer cells harboring either endogenous or 
overexpressed AR. Finally, genome-wide correlations of CCP revealed that elevated expression of 
the Fanconi Anemia pathway genes FANCA, FANCI, FANCD2, BRCA1 and BRCA2 were found in 
tumors with high CCP activity and that down-regulating these genes with siRNA in prostate cancer 
cell lines markedly reduced their growth. In summary, this study suggests that there is limited 
molecular heterogeneity between metastatic tumors from any given patient, a feature that might 
enable treatment selection based on a biopsy obtained from a single metastatic site. 
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